Table 1.
Demographic, Anthropometric, Behavioral, Clinical, and Human Immunodeficiency Virus–Related Characteristics
| Parameter | Enrolled Patients, No. (%)a (n = 101) |
|---|---|
| Age, median (IQR), y | 37.9 (IQR 31.1–41.0) |
| Female sex | 53 (52.5) |
| BMI, median (IQR)b | 23.1 (20.3–25.9) |
| BMI ≤18.5b | 6 (5.9) |
| History of fracture | 9 (8.9) |
| History of fragility fracture | 0 (0) |
| Family history of hip fracture | 0 (0) |
| Current smoking | 2 (2) |
| Current alcohol use | 15 (14.9) |
| Previous long-term steroid use | 0 (0) |
| Findings in women, no. (% of female population) | |
| Menopausal status | 5 (9.4) |
| Hormonal contraceptive use | 13 (24.5) |
| DMPA use | 4 (7.5) |
| WHO clinical stage | |
| I | 1 (1) |
| II | 17 (16.8) |
| III | 25 (24.8) |
| IV | 58 (57.4) |
| CD4 cell count, median (IQR), cells/μL | |
| Nadir | 48 (12.3–139.3) |
| Current | 468 (326.5–674.0) |
| Current HIV load <20 copies/mL | 80 (79.2) |
| ART duration, median (IQR), y | 12.2 (10.6–13.1) |
| TDF treatment | |
| Current | 61 (61) |
| Exposure | 65 (65) |
| Duration, median (IQR), mo | 48.3 (32.8–86.8) |
| PI treatment | |
| Current | 44 (44) |
| Exposure | 44 (44) |
| Duration, median (IQR), mo | 65.7 (35.9–97.0) |
| Current serum creatinine, median (IQR), mg/dL | 0.7 (0.6–0.9) |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; DMPA, depot medroxyprogesterone acetate; HIV, human immunodeficiency virus; IQR, interquartile range; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate; WHO, World Health Organization.
aData represent no. (%) of patients unless otherwise specified.
bBMI calculated as weight in kilograms divided by height in meters squared.